PTO/SB/92 (09-04)

Approved for use through 07/31/2006. OMB 0561-0031 Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

perwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



10/568572

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

> Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Registration Number, if applicable

each submitted paper.

une 26, 2006. Typed or printed name of person signing Certificate 54, 453 201 312 5084 Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify

Supplemental IDS Statement (2pgs) IDS-1449 (2pgs)

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Docket: 453-US-PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

Heidi Lopez de Diego

Application No.:

10/568,572

Filed:

February 16, 2006

Group Art Unit:

Not Yet Assigned

Examiner:

Not Yet Known

For:

Succinate and Malonate Salt of Trans-4-((1R,3S)-6-

Chloro-3-Phenylindan-1-yl)-1,2.

2-trimethylpiperazine and the Uses as a Medicament

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir/Madam:

In order to ensure compliance with applicants' duty of disclosure under 37 C.F.R. §1.56 and §1.97(a)-(d), applicants request that the following reference be considered and made of record in the above-identified application:

- 1. WO 93/08799 (Smith-Kline Beecham Corporation, 13 May 1993;
- 2. Klaus P. Bogeso in "Drug Hunting, the Medicinal Chemistry of 1-Piperazino-3-phenylindans and Related Compounds", **1998**, *ISBN 87-88085-10-4*;
- 3. Bogeso J. Med. Chem. 1983, 26, 935;
- 4. J. Org. Chem. 1990, 55, 4822;
- 5. Froimowits, et al., J. Med. Chem. **2000**, 43, 4981-4992;
- 6. Millan et al., JPET, 2000, 292, 38-53;
- 7. Seeman Science and Medicine 1995, 2, 28-37;
- 8. D.N.Eder, Current Opinion in Investigational Drugs, 2002, 3 (2):284-288;
- 9. P. Willner, Brain. Res. Rev. 1983, 6, 211-224, 225-236 and 237-246; and
- 10. Bogeso J. Med. Chem., 1985, 28, 1817-182.

Heidi Lopez de Diego Appln No: 10/568,572

Filed: February 16, 2006

Page 2 of 2

Applicants are filing this Supplemental Information Disclosure Statement under 37 C.F.R.

1.97(b)(3), before the mailing of a first Office Action on the merits. Accordingly, no fee is

deemed necessary in connection with the filing of this Supplemental Information

Disclosure Statement. However, in the event that a first Office Action has been mailed

but has not yet been received by applicant or connected with the application filed in the

undersigned attorney's office, applicants hereby request, pursuant to 37 C.F.R.

§1.98(c)(2), consideration of this Supplemental Information Disclosure Statement, and

authorization is hereby given to charge to Deposit Account No. 503201, ONE HUNDRED

AND EIGHTY DOLLARS (\$180.00), which is the amount of the fee under 37 C.F.R.

1.17(p), for filing a Supplemental Information Disclosure Statement pursuant to 37 C.F.R.

1.97(c)(2).

It is requested that the Examiner consider the above information and that a copy of the

enclosed Form PTO/SB/08a be initialed and returned indicating that such information has

been considered. Applicants respectfully request that the Examiner make the cited

references of record in the subject application.

If a telephone interview would be of assistance in advancing the prosecution of the

subject application, applicants' undersigned attorney invites the Examiner to telephone

her at the number provided below.

Respectfully submitted,

Nicholas J. Sisti, Ph.D., J.D.

Registration No. 54,453

Lundbeck Research USA, Inc.

215 College Road

Paramus, New Jersey 07652

(201) 312-5084 (phone); (201) 225-9571 (fax)

June 26, 2006

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

JUN 2 6 2006 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction re required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known			
Application Number	10/568572		
Filing Date	February 16, 2006		
First Named Inventor	Heidi Lopez de Diego		
Art Unit	Not Yet Assigned		
Examiner Name	Not Yet Known		
Attorney Docket Number	453-US-PCT		

			U. S. PATENT D	OCUMENTS	
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (d known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-		****	· · · · · · · · · · · · · · · · · · ·
		US-			
		US-		*****	
		US-			

		FOREIG	N PATENT DOCU	JMENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	
		Country Code ^{3 -} Number ^{4 -} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T⁵
		WO 93/08799	05-13-1993	Smith-Kline Beecham Corp.		
<u> </u>						
	l		İ	1		/

	_	
Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any complete on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known		
3333333				Application Number	10/568572	
INFO	DRMATION	I DIS	CLOSURE	Filing Date	February 16, 2006	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Heidi Lopez de Diego	
(Use as many sheets as necessary)				Art Unit	Not Yet Assigned	
(cooled many checks as necessary)				Examiner Name	Not Yet Known	
Sheet	2	of	2	Attorney Docket Number	453-US-PCT	

	· · · · · · · · · · · · · · · · · · ·	
	NON PATENT LITERATURE DOCUMENTS	
Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
	Klaus P. Bogeso in "Drug Hunting, the Medicinal Chemistry of 1-Piperazino-3-phenylindans and Related Compounds", 1998, ISBN 87-88085-10-	
	Bogeso J. Med. Chem. 1983, 26, 935,	
	J. Org. Chem. 1990, 55, 4822	
 - - -	Froimowits, et al., J. Med. Chem. 2000, 43, 4981-4992	
	Millan et al., JPET, 2000, 292, 38-53	
	Seeman Science and Medicine 1995, 2, 28-37	
	D.N.Eder, Current Opinion in Investigational Drugs, 2002, 3 (2):284-28	
	P. Willner, Brian. Res. Rev. 1983, 6, 211-224, 225-236 and 237-2	
	Bogeso J. Med. Chem., 1985, 28, 1817-1828	
		Cite No.¹ Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. Klaus P. Bogeso in "Drug Hunting, the Medicinal Chemistry of 1-Piperazino-3-phenylindans and Related Compounds", 1998, ISBN 87-88085-10- Bogeso J. Med. Chem. 1983, 26, 935, J. Org. Chem. 1990, 55, 4822 Froimowits, et al., J. Med. Chem. 2000, 43, 4981-4992 Millan et al., JPET, 2000, 292, 38-53 Seeman Science and Medicine 1995, 2, 28-37 D.N.Eder, Current Opinion in Investigational Drugs, 2002, 3 (2):284-28 P. Willner, Brian. Res. Rev. 1983, 6, 211-224, 225-236 and 237-2

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.